Emerging nanomedicine for liver diseases treatment Authors: Yawen Zhu, Dongxue Ge, Jinglin Wang, Hao Sun, Wei Li, Haozhen Ren Published: 2025 ABSTRACT AbstractThe liver is the largest parenchymal organ in the human body, crucial for overall health. However, hepatic diseases have become a global epidemic, causing significant burdens. While traditional therapies for liver diseases such as hepatic fibrosis, non-alcoholic fatty liver disease, and hepatocellular carcinoma have shown limited efficacy and significant side effects, the advent of nanotechnology has introduced novel and promising therapeutic strategies. Nanomedicine, with its excellent biocompatibility, surface modification capabilities, and high targeting ability, has the potential to revolutionize liver disease treatment. Here, we systematically review the latest advancements in nanomaterials for liver diseases, focusing on innovative nanocarriers such as exosomes, liposomes, microneedle technologies, biomimetic microfibers, and emerging platforms. We highlight critical gaps in current nanomedicine research, including biocompatibility and toxicity concerns, scalability and cost-effectiveness of production, and the need for personalized medicine and patient-specific nanotherapies. By addressing these challenges, nanotechnology can provide a multifunctional and powerful platform to significantly improve liver health and overcome existing limitations in clinical translation.Graphical Abstract Keywords: Liver disease, Nanomedicine, Biomedical engineering, Treatment outcome Introduction The liver, the most substantial organ in the human body, is notably vulnerable to injury [1]. A spectrum of hepatic pathologies, including fibrosis, non-alcoholic fatty liver disease (NAFLD), and hepatocellular carcinoma (HCC), often represent interconnected stages of progressive liver damage [2]. Chronic liver injury, irrespective of etiology, can trigger a response that leads to hepatic fibrosis characterized by excessive extracellular matrix deposition. This fibrotic microenvironment, in turn, fosters a protumorigenic niche [3]. Notably, NAFLD, driven by metabolic dysregulation and lipid accumulation, has emerged as a leading cause of liver fibrosis and a rapidly growing etiology of HCC [4]. This pathological continuum from steatosis and inflammation in NAFLD, to fibrosis, and ultimately to HCC, highlights the interconnected nature of these conditions. Among these, HCC is the fifth most common cancer worldwide, with over 600,000 deaths annually [5, 6]. Additionally, approximately 3.3 million people are diagnosed with alcohol-related liver diseases each year, accounting for 5.9% of global deaths [7]. Given the high prevalence and mortality associated with these conditions, early identification, accurate diagnosis, and effective treatment of liver diseases are of paramount importance [8]. Traditional therapeutic interventions, such as pharmacotherapy, interferon therapy, and liver transplantation, have demonstrated some efficacy. However, these approaches are often limited by issues such as drug resistance, rapid metabolism, and significant side effects [9, 10]. These limitations highlight the urgent need for innovative therapeutic strategies that can overcome these challenges and improve clinical outcomes [11]. Nanotechnology has achieved remarkable progress in the diagnosis and treatment of hepatic diseases [12]. Since the inception of liposomes in 1970, a plethora of nano-carriers has been engineered. These carriers encompass a range of entities, such as nanoparticles (e.g., exosomes and liposomes), microneedle technology, biomimetic microfibers, and innovative nano-carriers (including dendritic polymers and polymeric nanoparticles) [13]. The core strength of nanomedicine lies in its ability to enhance drug solubility, prolong circulation half-life, and, most importantly, enable active targeting. This allows for the specific delivery of therapeutic agents to key cell types involved in disease progression, such as activated hepatic stellate cells in fibrosis, inflamed hepatocytes in NAFLD, or neoplastic cells in HCC [14]. For instance, nanoparticles can be engineered to deliver antifibrotic drugs directly to activated HSCs, thereby reducing ECM production and fibrosis progression [15]. Similarly, nanocarriers can encapsulate molecules that target metabolic pathways implicated in NAFLD or oncogenic pathways in HCC, improving therapeutic outcomes while minimizing systemic side effects. Furthermore, the incorporation of biomimetic features into synthetic materials can yield optimal physicochemical properties and functionalities, surmounting biological barriers within the liver and bolstering targeting precision [16]. This significantly ameliorates the deficiencies of conventional nano-medicines, paving the way for their extensive application in the management of diverse, yet interconnected, liver diseases. This review aims to provide a comprehensive and updated overview of the emerging field of nanomedicine, with a particular emphasis on its application value in the treatment of clinical liver diseases. Unlike previous reviews that have primarily focused on traditional nanocarriers or specific disease states, this review offers a novel and integrated perspective by covering the full spectrum of nanomedicine advancements, from basic science to clinical translation. We begin by briefly introducing the pathophysiological mechanisms behind various liver diseases, focusing on liver fibrosis, NAFLD, and HCC, as well as the nanomedicines developed to address these issues. Subsequently, we critically evaluate the previous literature to extract the latest advancements in nanomedicine in liver treatment, highlighting the unique contributions of emerging nanocarriers and biomimetic strategies. Additionally, we summarize the advantages and limitations of nanomedicines applied in liver diseases based on the relevant literature, providing a balanced view of the field. Moreover, we address the critical issues of biocompatibility and toxicity of nanomedicines, as well as related regulatory and ethical concerns, which are often underrepresented in other reviews. Finally, we present unique insights into the scalability and cost-effectiveness of nanomedicine production, the prospects of personalized medicine, and patient-specific nanotherapies, offering forward-looking perspectives for future research and development (Fig. 1). Schematic illustrating the release mechanism of drugs carried by emerging nanoparticles (NPs) and nanocarriers for the treatment of liver diseases Molecular therapeutic drugs for liver disease A plethora of clinical strategies are employed for the management of liver diseases, encompassing surgical interventions, pharmacotherapy, and hepatic transplantation [17]. These modalities, along with their associated pharmaceuticals, have garnered considerable clinical success [18]. However, conventional therapeutics are not without their challenges, which impede the efficacy of current liver disease treatments [19]. For instance, the lack of specificity in traditional drugs can foster drug resistance and exacerbate toxic side effects; hepatic biological barriers also curtail the amount of medication that penetrates systemic circulation, thereby dampening therapeutic outcomes (Table 1) [20, 21]. Thus, there is an imperative need for the advancement of innovative pharmaceuticals for liver disease treatment [22]. Table 1Therapeutic drugs, encapsulation strategies and targets for liver diseasesLiver diseaseTherapeutic drugDelivery carrierAdvantagesDisadvantagesTarget pointsReferenceNon-alcoholic fatty liver disease (NAFLD)PioglitazoneMesoporous silica nanoparticlesImproving steatosis and histological alterationsIncreasing bone lossexacerbating heart failure.PPAR-γ[23, 24]Obeticholic AcidSelf-assembly of lecithin and olive oilSuitability for a variety of clinical situations requiring reduced bile acid synthesisIncreased of total cholesterol levels, coupled with a decrease in HDL cholesterol.FXRagonist[25, 26]α-TocopherolComposed of the hydrophilic groups of phosphoethanolamine and succinic acid.Scavenging ROS and lipid peroxidationInhibiting f HMG-CoAR and cholesterol accumulationLong-term use of high doses is associated with an increased risk of hemorrhagic strokeAntioxidant[27, 28]PentoxifyllineEncapsulated in lecithin/chitosan nanoparticlesReducing liver enzymesImprovement of histologyExacerbating fatty liverTNF-αinhibitor[29, 30]Hepatic carcinomaSorafenibEncapsulate by poly lactic-co-glycolic acidTreating patients with advanced liver cancer who cannot undergo surgeryLack of molecular markers to predict therapeutic outcomesSignificant toxic side effectsMulti-kinaseinhibitor[31, 32]BevacizumabHuman serum albumin nanoparticlesTreatment for colon cancer and ovarian cancerCausing side effects such as lower blood pressure, heart problems, and bleedingVEGFRinhibitor[33, 34]EverolimusSilver nanoparticlesHigher selectivity reduction may occur during use with incomplete target inhibition and feedback activation of precancerous signalsHigh blood pressureImpaired kidney functionmTORinhibitor[35, 36]Hepatic fibrosisPirfenidoneMultifunctional constructs synthesized using dicoumarol derivativesAlleviating inflammation, steatosisImproving liver functionMild gastritisNauseaTGF-β1inhibition[37, 38]HalofuginoneNanogels formed by the combination of hydrogen fluoride and the block copolymer of poly (ethylene glycol)-poly (aspartic acid)Alleviating liver lesions and fibrous connective tissue proliferationGastrointestinal reactionsTolerance productioMetalloproteinaseinhibition[39, 40]BelapectinGold nanoparticles.Well-tolerated for advanced liver fibrosisCross-resistance with other antibioticsPPARagonist[41, 42] Therapeutic drugs, encapsulation strategies and targets for liver diseases Increasing bone loss exacerbating heart failure. FXR agonist Scavenging ROS and lipid peroxidation Inhibiting f HMG-CoAR and cholesterol accumulation Reducing liver enzymes Improvement of histology TNF-α inhibitor Lack of molecular markers to predict therapeutic outcomes Significant toxic side effects Multi-kinase inhibitor VEGFR inhibitor High blood pressure Impaired kidney function mTOR inhibitor Alleviating inflammation, steatosis Improving liver function Mild gastritis Nausea TGF-β1 inhibition Gastrointestinal reactions Tolerance productio Metalloproteinase inhibition PPAR agonist Hepatic fibrosis Hepatic fibrosis denotes the pathological accumulation of extracellular matrix (ECM) proteins following liver injury, a reparative response gone awry [43]. Central to this process is the activation of hepatic stellate cells, which serve as the primary conduits for ECM protein synthesis [44]. YAP and TAZ, key transcriptional co-activators downstream of the Hippo signaling pathway, are widely recognized as central drivers of liver fibrosis [45]. In fibrotic liver tissues, the inactivation of the Hippo pathway results in the aberrant activation of YAP/TAZ and their translocation into the nucleus, thereby initiating a cascade of gene programs that promote the activation of hepatic stellate cells and drive the progression of liver fibrosis [46]. Thus, modulating the stiffness of the ECM to transduce and regulate the YAP/TAZ signaling pathway is essential for inhibiting the activation of hepatic stellate cells and the development of liver fibrosis. Therefore, targeting hepatic stellate cells represents a crucial strategy for inhibiting liver fibrosis [47]. Wang et al. have elucidated that the expression of YAP is significantly upregulated during the progression of liver fibrosis [48]. At the mechanistic level, YAP binds to the Gata6 promoter, thereby inhibiting its transcription. This inhibition disrupts the normal maturation process of hepatic sinusoidal endothelial cells, which in turn exacerbates the development of liver fibrosis. To counteract this pathological process, targeted delivery of hyaluronic acid-polyethyleneimine nanoparticles specifically to hepatic sinusoidal endothelial cells has been demonstrated to effectively alleviate the progression of liver fibrosis in murine models. These findings underscore the potential of targeting YAP and hepatic sinusoidal endothelial cells as a therapeutic strategy for mitigating liver fibrosis. In addition to the elasticity and rigidity of nanocarriers, the surface properties of nanocarriers, particularly their surface charge and hydrophobicity, directly determine the delivery efficiency to hepatic stellate cells [49]. Positively charged nanocarriers can strongly bind to negatively charged activated hepatic stellate cells through electrostatic adsorption, significantly enhancing cell internalization efficiency [50]. However, this positive charge is prone to adsorption by serum proteins and rapid clearance by immune cells in the liver, such as Kupffer cells. In contrast, negatively charged or neutral nanoparticles can effectively reduce protein adsorption, prolong circulation time in the blood, and increase the likelihood of passing through the fenestrations of the hepatic blood sinusoids to enter the liver interstitial space. Pan et al. focused on studying the influence of the surface charge of lipid nanoparticles on their liver-targeting ability and in vivo distribution [51]. Their results showed that negatively charged nanodelivery systems loaded with retinol significantly enhanced liver uptake efficiency and prolonged retention time. Hydrophobicity also profoundly affects the interaction between nanocarriers and the cell membrane. Highly hydrophobic carriers have a stronger affinity for the cell membrane’s phospholipid bilayer and are more likely to be engulfed by cells. However, excessive hydrophobicity in the complex in vivo environment can lead to immune clearance and reduced penetration to the target site due to increased particle size [52]. Thus, an ideal nanocarrier must achieve a delicate balance between hydrophobicity and hydrophilicity. Lee et al. examined the distribution of surface-modified silica nanoparticles in mice and found that hydrophobic silica nanoparticles were more efficiently delivered to the liver when injected intraperitoneally [53]. Surface modification of nanoparticles can therefore be utilized to enhance liver delivery efficiency. Overall, optimizing the surface properties of nanocarriers is crucial for improving targeted delivery to hepatic stellate cells and enhancing therapeutic efficacy in liver fibrosis. The majority of pharmacological interventions for liver fibrosis are currently in Phase II and III of preclinical trials [54]. However, certain molecular therapies have shown promise, including the antifibrotic effects of glucocorticoids and angiotensin receptor antagonists [55]. Pirfenidone, an antifibrotic agent, is in the clinical phase II of application [56]. Xi et al. utilized male C57BL/6J mice to establish a liver fibrosis model, and the administration of pirfenidone indicated that it targets glutaredoxin-1 to suppress hematopoietic stem cell activation and liver fibrosis [57]. These findings position glutaredoxin-1 as a potential therapeutic target for liver fibrosis. Donafenil, a novel oral multikinase inhibitor, was tested by Zheng et al. in a thioacetamide-induced liver fibrosis model. Administering 1 mg/kg/day of Donafenil confirmed its ability to inhibit the activation of human hepatic stellate cells, thereby exerting a multi-targeted antifibrotic effect [58]. However, the poor bioavailability of pirfenidone and the lack of tumor specificity have limited its efficacy. Zhou et al. aimed to address the limitations of pirfenidone and developed a fluorescent nanoplatform targeting the liver [38]. This system is based on the combination of fructose and silane-modified organic frameworks, which enhances the drug stability and drug loading capacity. In vitro tests showed that the nanomaterials loaded with pirfenidone effectively reduce tumor cells. Similarly, Li and his team developed a nano-delivery system, aiming to enhance the targeting ability and reduce the toxicity of pirfenidone in the body [59]. They developed a self-assembling system, fibroblast activation protein-α-responsive nano-capsules, which target liver fibrosis peptides to protect pirfenidone and transport it to the fibrotic liver. These results indicate that nanomaterials have considerable potential for improving the limitations of traditional drugs and for targeted drug delivery. Ferroptosis is an oxidative stress-dependent form of regulated cell death that has become a major focus of recent research. Accumulating evidence underscores its pivotal role in the pathogenesis of liver fibrosis [60]. Unlike apoptosis and necrosis, ferroptosis is a distinct programmed cell death pathway. It is mechanistically linked to glutathione redox and is characterized by the accumulation of lipid peroxidation. Given this, inhibiting ferroptosis in liver cells emerges as a crucial factor in reversing liver fibrosis. However, the precise connection between their anti-fibrotic mechanisms and ferroptosis in liver cells remains to be fully elucidated. In this context, Yu et al. introduced a novel nano-delivery platform focused on inducing ferroptosis [61]. This platform employs vitamin A nanoparticles to load artemisinin. Upon oral administration, artemisinin depletes glutathione peroxidase 4 and glutathione, thereby effectively triggering ferroptosis. In vivo experiments have demonstrated that this strategy can induce significant ferroptosis and effectively mitigate liver fibrosis. Similarly, Lai and colleagues utilized self-assembly technology to combine ursolic acid nanoparticles with carbon dots [62]. This system is fabricated using ursolic acid as the precursor through a straightforward one-step hydrothermal process [63]. Experimental results have confirmed that this nano-enzyme possesses an excellent capacity to induce ferroptosis. Collectively, these research endeavors highlight that nanoparticle-based delivery of ferroptosis inducers holds promise for improving liver fibrosis. Currently, the BMS-986,263 lipid nanoparticles (NCT03420768) undergoing phase II clinical trials can achieve targeted delivery by exploiting the uptake characteristics of liver stellate cells for vitamin A. This is a siRNA targeting heat shock protein 47 (HSP47), which is encapsulated in vitamin A-conjugated lipid nanoparticles. HSP47 is a key protein for collagen maturation and is highly expressed in activated liver stellate cells. It can effectively reduce the biomarker levels of patients with liver fibrosis and has good safety. This provides an important basis for the clinical treatment of liver fibrosis using nanotechnology for targeted delivery of nucleic acid drugs. Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, which is influenced by factors such as obesity, insulin resistance, dyslipidemia, and genetic predispositions, leading to lipid accumulation in the liver [64]. Complications such as lipotoxicity and oxidative stress can exacerbate hepatocellular damage and demise. AMPK is a key regulator of energy balance and metabolism, involved in various physiological metabolic pathways [65]. AMPK can directly or indirectly affect the activity and expression of multiple transcription factors, including members of the peroxisome proliferator-activated receptor (PPAR) family [66]. PPARs are ligand-activated transcription factors in the nuclear receptor superfamily, playing important roles in regulating lipid metabolism, energy homeostasis, inflammation regulation, and cell differentiation. Among them, PPARα and PPARγ are particularly important in liver lipid metabolism: PPARα promotes fatty acid β-oxidation, while PPARγ promotes lipid uptake and storage, and their dysregulation is associated with steatosis and the development of fatty liver disease. Therefore, regulating the AMPK pathway holds great potential in improving the development of NAFLD. Nanodelivery systems precisely deliver drugs while activating the two major metabolic regulatory centers, AMPK and PPARα [67]. On one hand, AMPK rapidly regulates enzyme activity through phosphorylation events [68]; on the other hand, PPARα achieves long-term regulation by regulating gene expression. The two work together, reversing lipid metabolism disorders from multiple aspects, ultimately achieving a comprehensive therapeutic effect of improving liver steatosis, inflammation, and insulin resistance, providing a highly promising nanomedicine strategy for the treatment of NAFLD. For instance, Brandts and his team confirmed that polystyrene nanomaterials interfere with lipid metabolism through the PPAR system and affect the functionalization of macrophages [69]. Li et al. unlocked the use of polymer nanoparticle carriers to deliver MST1 for the treatment of NAFLD [70]. The HCP/MST1 complex significantly improved liver insulin resistance sensitivity through the AMPK/SREBP-1c pathway, reducing liver damage and lipid accumulation [71]. In summary, the regulation of the AMPK and PPAR pathways via nanodelivery systems offers a promising therapeutic strategy for NAFLD, effectively improving liver steatosis, inflammation, and insulin resistance. Researchers have explored the therapeutic potential of hyodeoxycholic acid (HDCA), a bile acid modified by the gut microbiome, in treating nonalcoholic steatohepatitis (Fig. 2A-B) [72]. The association between serum levels of bile acids was explored and grouped by clinical investigation in patients with nonalcoholic steatohepatitis and the normal population (Fig. 2C-D). Their study in adult male mice indicated that HDCA targets intestinal farnesol X receptors and enhances the abundance of probiotic species in the gut, while activating hepatic CYP7B1 and PPARα through the enterohepatic axis (Fig. 3A-C). However, further research in additional mouse models is necessary to understand the comprehensive effects of such molecular drugs on NAFLD [73]. HDCA alleviates NAFLD by regulating the enterohepatic axis. (A) Survey groups of clinical patients, including healthy controls and patients with NALFD. (B) Z-scores of serum HCA type/TBA in normal and diseased individuals. (C) Mouse model construction. (D) Representative histological staining of the liver including high-fat diet (CDAHFD) and HDCA group. Scale bar, 100 μm. Copyright©2023, Cell Metabolism The specific mechanism by which HDCA alleviates NAFLD. (A) The mRNA expression related to ferroptosis. (B) The mRNA expression related to liver inflammation. (C) KEGG functional pathways in mouse intestinal contents. Copyright©2023, Cell Metabolism Zhang and his team developed IMA-1, a small molecule with therapeutic potential for NAFLD. Their study in male mice and macaques demonstrated that IMA-1 disrupts the arachidonate 12-lipoxygenase–acetyl-CoA carboxylase 1 interaction, thereby treating NAFLD without inducing hyperlipidemia [74]. Although drugs such as OCA and Elafibranor have pharmacological benefits in treating MAFLD, these combinations suffer from poor solubility during oral administration and severe side effects, which severely limit their clinical application. In recent years, the use of nanocrystal-based delivery systems as a general approach for poorly soluble drugs has attracted significant research interest [75]. Lu and his colleagues combined nanocrystals with free drugs, significantly prolonging the bioavailability of OCA and enhancing cell permeability [76]. This is a non-carrier-based amorphous nano-crystal composed of OCA and the cholesterol-lowering atorvastatin, formed through instantaneous assembly. It has been determined that the total drug loading capacity of these nano-crystals is approximately 90%. In addition to these advantages, the nanocarriers also improved the loading capacity of active drugs and the accumulation of toxic agents related to excipients in nanomedicine [77, 78]. Pentoxifylline has been proven to significantly reduce liver lipid accumulation, lower blood lipid levels, and improve insulin resistance, thereby treating non-alcoholic fatty liver disease [79]. It is worth noting that pentoxifylline is a highly water-soluble hemorheological drug, and studies have shown that its oral bioavailability is only 20%. Varshosaz and his colleagues, in order to overcome the first-pass effect challenge brought by pentoxifylline, prepared solid lipid nanoparticles encapsulating pentoxifylline [80]. The liposomes were prepared based on Stearic acid and Cetyl alcohol using the ultrasonic solvent evaporation emulsification technique, and their oral bioavailability was enhanced through homogenization of the nanoparticles and ultrasonic methods. It was proven that the solid lipid nanoparticles encapsulating pentoxifylline had a 5.23-fold higher bioavailability than the theobromine monomer. Similarly, Ashay dedicated himself to researching the in vivo administration of pentoxifylline and successfully developed a nano-emulsified drug delivery system [81]. First, the lipid samples were extracted with methanol. Then, a dilution solution was prepared using the mobile phase and injected into the HPLC. The pentoxifylline was eluted at a fixed time. It was observed that within the range of 200 to 750 ng/mL, the regression coefficient was greater than 0.992. The nanoemulsified drug delivery system was successfully prepared. Subsequently, by forming nano-spheres upon contact with biological fluids after oral administration, the in vivo pharmacokinetic parameters of the theobromine were significantly enhanced. Nanomedicines for the clinical treatment of NAFLD include the following types: HTD1801 has completed the Phase II clinical trial (NCT03656744) [82]. This drug is based on the multi-component nanoparticle technology of bile acid derivatives and improves liver metabolic disorders and inflammatory responses by targeting the FXR receptor and TGR5 receptor; NGM282 demonstrated significant efficacy in the Phase II clinical trial (NCT02443116) [83]. This drug is a nanoparticle formulation based on fibroblast growth factor 19 analogues, which prolongs the half-life and enhances liver targeting through pegylation modification. HCC HCC is a prevalent malignant tumor within the digestive system, characterized by its asymptomatic nature, propensity for metastasis, and limited treatment opportunities [84, 85]. The tumor microenvironment (TME) is the cornerstone and core of comprehensive immunotherapy for HCC [86]. Its core feature is the immunosuppressive state formed under the background of chronic liver disease. This state is mainly dominated by the infiltration and activation of immunosuppressive cells such as myeloid-derived suppressor cells, M2-type tumor-associated macrophages, and regulatory T cells [87]. These cells secrete inhibitory cytokines such as TGF-β and IL-10, and express immune checkpoint molecules such as PD-L1, jointly weakening the effector functions of cytotoxic CTLs and natural killer cells, thereby promoting tumor immune escape [88]. The main types of tumor immunotherapy include immune checkpoint inhibitors and oral small molecule drugs, etc. However, systemic administration of immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) often faces limitations such as poor tumor targeting, difficulty in penetration, and triggering autoimmune side effects, which restrict the full exertion of their efficacy [89]. It is worth noting that nanocarriers such as liposomes and polymer nanoparticles can precisely deliver immunomodulatory drugs to the tumor region [90]. This targeted strategy not only passively accumulates at the tumor site through enhanced permeability and retention effects, but also actively recognizes tumor-associated cells through surface modification. This significantly increases the local concentration of the drug in the TME and significantly reduces off-target toxicity to normal tissues [91]. The nanobodies proposed by the Jeon team targeting PD-L1 confirmed the excellent performance of nanocarriers [92]. This method is based on a computational process for optimizing the design of nanobodies and is supplemented by robust in vitro validation. It shows enhanced sensitivity and selectivity in the analysis of extracellular vesicles. Moreover, the PD-L1 nanobodies are also effective in inhibiting immune checkpoints. Therefore, nanomedicine is of great significance for the remodeling of TME [93]. Furthermore, targeted drug therapies for HCC have made significant advances, with some exhibiting high specificity and minimal toxic side effects [94]. As researchers delve into the mechanisms and efficacy of molecular drugs, an array of pharmaceuticals has been incorporated into the standard treatment guidelines for HCC [95, 96]. Current treatments focus on targeting specific molecules or pathways that inhibit the proliferation and spread of cancer cells [97]. For instance, drugs like regorafenib impede cancer cell signaling by suppressing tyrosine kinase activity, while tamoxifen and others curb cancer cell growth and metabolism by inhibiting the mammalian target of rapamycin (mTOR) pathway [98, 99]. Sorafenib, the first drug approved for targeted HCC treatment, is widely utilized as an oral multi-kinase inhibitor that targets tyrosine kinase receptors [106, 107]. It suppresses tumor growth by downregulating the Raf/MEK pathway and inhibits angiogenesis by targeting VEGFR receptors [108]. Combination therapies, such as sorafenib with Asiatic acid, have shown synergistic effects on protein levels of cyclin D1 and SKP2, and also modulate JNK1/2 signaling to inhibit ferroptosis in HCC cells [109]. It is worth noting that the combination therapy of sorafenib nanoparticles shows significant advantages in in vivo pharmacokinetics. The integration of nanoparticles and sorafenib can effectively prolong the drug half-life and enhance tumor targeting [110]. The delivery system not only improves the water solubility and bioavailability of sorafenib, but also increases the accumulation of the drug in the tumor site through an active targeting mechanism, thereby maintaining efficacy at lower doses and reducing toxic reactions (Table 2). Table 2In vivo pharmacokinetics of Sorafenib for HCCNanoparticlesLoading methodAnimal modelGroupDoseHalf-life (t1/2, h)Time to peak (tmax, h)ReferenceButadiene-block-ethylene oxideCo-solventBALB/c miceFree-sorafenib15 mg/kg42.934.00[100]SorafenibNanoparticles15 mg/kg91.384.00Polyethylene glycol- modified long-circulating nanoliposomes were used for delivering sorafenibReverse evaporationBalb/c-nu miceFree-sorafenibGive 200 µg every other day for 2 weeks10[101]Sorafenib nanoparticlesGive 200 µg every other day for 2 weeks10Polyethylene glycol-PDLLARing-opening polymerizationICR miceFree-sorafenib20 mg/kg8.22 (± 2.35)0.08 (± 0.00)[102]Sorafenib nanoparticles20 mg/kg12.92 (± 0.57)0.08 (± 0.00)Polyethylene glycol galactoseCarbodiimide coupling reactionBALB/c miceFree-sorafenib25 mg/kg6.58 (± 0.58)4.36 (± 0.20)[103]Sorafenib nanoparticles25 mg/kg16.75 (± 1.09)4.00 (± 0.00)Apolipoprotein E peptide-decorated disulfideRing-opening copolymerizationBALB/c miceFree-sorafenib6 mg/kg5.5[104]Sorafenib nanoparticles6 mg/kg6.88Castor oil, phosphate-buffered salineRotary evaporatorSwiss miceFree-sorafenib30 mg/kg50.93 ± 0.17417.33 ± 0.24[105]Sorafenib nanoparticles30 mg/kg12.96 ± 0.1779.6 ± 0.1 In vivo pharmacokinetics of Sorafenib for HCC Free- sorafenib Sorafenib Nanoparticles However, according to statistics, long-term use of sorafenib is prone to developing drug resistance. Wang et al. addressed this limitation by developing an oxide graphite diyne drug-loading platform [111]. This system loads sorafenib through specific peptides as a tool for targeting HCC. Firstly, graphdiyne is oxidized under the action of concentrated nitric acid and sulfuric acid. Subsequently, the carboxyl groups are activated through the combined action of carbodiimide and N-hydroxysuccinimide to form stable amide bonds. Finally, through the π-π stacking interaction between the aromatic rings, sorafenib is co-loaded onto the graphdiyne nanosheets. This nano drug-loading platform enhances the targeting and stability of the drug and can continuously induce ferroptosis in tumor cells, which has potential clinical application value and is different from traditional drugs. However, sorafenib was found to have certain side effects, and the anti-angiogenic treatment based on its efficacy was also discouraging. Liu et al. developed a lipid nanoparticle targeting CXCR4 to overcome the toxicity and systemic side effects brought by traditional sorafenib [112]. This kind of liposome consists of DOPC, DOPA, and cholesterol. In addition, VEGF and CXCR4 antagonists AMD3100 were added for targeted delivery in the treatment of HCC [113]. Bufalin, as one of the main components of the drug for liver cancer treatment, is an inhibitor targeting HIF-1α [114]. Li et al. developed a synergistic nanoparticle that restores the sensitivity of liver cancer cells to sorafenib [115]. Zinc was dissolved in an appropriate amount of methanol, and then 2-MIM was dropped onto Zn (NO3)2. After stirring at room temperature and centrifugation, ZIF-8 was obtained. The encapsulation of ZIF-8 within a continuous lipid bilayer serves to prevent premature drug leakage. This design is intended to enhance the formulation’s tumor-targeting capability and delivery efficiency, thereby achieving synergistic inhibition of both angiogenesis and tumor growth for improved combination therapy of liver cancer [116]. Similarly, Zhu et al. combined the Traditional Chinese medicine paclitaxel with liposomes. They prepared lipid membrane materials by the film hydration method instead of cholesterol, enabling the liposomes to target cancer cells by recognizing glucose transporter 1. They also combined paclitaxel with liposomes using the ultrasonic method. The results showed that this functional liposome carrying paclitaxel could significantly promote tumor cell apoptosis, reshape the liver immune microenvironment, and improve drug resistance [117]. Kong et al. reviewed the extensive application of nanoparticles for chemotherapy drug delivery and multimodal imaging in medical contexts (Fig. 4A) [118]. Notably, nanoparticles loaded with sorafenib (SOR-LNP) primarily target HCC through the nanoparticle structure described in the legend (Fig. 4B). Structural diagram of Sorafenib combined with nanoparticles targeting HCC. (A) Sorafenib binds to silica nanoparticles to target pH-responsive drug release in HCC. (B) Targeting liver lesions based on lipid nanoparticle supported sorafenib. Copyright©2021, Theranostics In the treatment of HCC, the clinical translation of nanomedicines has also made significant progress. Among them, liposomal doxorubicin is the liposome drug carrier for thermal activation that has been used in human clinical trials (NCT02112656) [119]. It is suitable for treating larger tumors in the liver because the heat generated by ablation will activate the nano-delivery system, thereby releasing a large amount of drugs to the periphery; Ursolic acid nano-liposomes, as a chemotherapy nanomedicine, delivers ursolic acid through nano-liposomal injection and has already undergone clinical trials in China in 2023 (CTR20230593); Additionally, nucleic acid-based nanomedicines DCR-MYC, which encapsulates MYC siRNA in lipid nanoparticles, targets and inhibits the expression of the oncogene MYC in HCC. The related clinical trials (NCT02314052) have explored its safety and anti-tumor efficacy [120]. These studies demonstrate the potential of nanocarrier technology in improving drug targeting and reducing side effects, providing new strategies for the treatment of HCC [121]. In conclusion, the research on molecular therapeutic drugs for liver diseases has made significant strides. Therefore, we have summarized the clinical trials mentioned above (Table 3). However, there are still some challenges, such as suboptimal targeting, rapid drug metabolism, and significant side effects, which limit their clinical efficacy. To address these limitations, advanced delivery systems such as nanocarriers offer a promising solution [122]. Nanocarriers, with their high liver-targeting ability, excellent anti-resistance properties, and low immunogenicity. Therefore, it is essential to conduct a detailed classification of nanocarriers and investigate the specific mechanisms by which they improve the treatment of liver diseases. This comprehensive approach will not only advance the field of liver disease therapy but also contribute to the broader understanding of nanomedicine applications in general diseases. Table 3The clinical trials of nanomedicines for liver diseasesNanoparticlesClinical trial numberLiver diseaseDrugReferenceBMS-986,263 lipid nanoparticlesNCT03420768Hepatic fibrosisVitamin A[123]Multicomponent nanoparticlesNCT03656744NAFLDBile acid derivatives[124]Polyethylene glycol nanoparticlesNCT02443116NAFLDFibroblast growth factor 19[125]Lipid nanoparticlesNCT02112656HCCDoxorubicin[126]Lipid nanoparticlesCTR20230593HCCUrsolic acid[127]Lipid nanoparticles DCR-MYCNCT02314052HCCNucleic acid[128] The clinical trials of nanomedicines for liver diseases Advances in nanomedicine for liver therapy In the contemporary era, the confluence of swift advancements in nanotechnology and escalating clinical demands has engendered an emergent, multidisciplinary discipline known as nanomedicine [129]. These nanomedicines exhibit distinctive biological properties that set them apart from conventional pharmaceutical molecules, thereby accentuating the benefits of nanoscale materials [130]. Firstly, the diminutive size of nanomaterials, which is sub-cellular, facilitates the surmounting of hepatic biological barriers, thereby optimizing the efficacy of pharmaceuticals [131]. Secondly, the incorporation of active targeting mechanisms enhances the precision with which drugs are delivered to the liver [132]. Lastly, the integration of therapeutics with diagnostics through the utilization of therapeutic nanomedicines offers patients a potent and cost-effective treatment modality [133]. Ubiquitous nanodrug delivery systems encompass nanospheres, microneedles, biomimetic microfibers, and a spectrum of polymeric nanoparticles. The approval of the first liposome-based nanomedicine, Doxil®, to the current available nanomedicines marks the continuous evolution of nanomedicine from simple drug delivery to precise, integrated and intelligent diagnostic and therapeutic approaches (Fig. 5) [134]. Key historical events in the application of nanomaterials for treating liver diseases While the overarching advantages of nanomedicine are significant, the choice of nanocarrier material, broadly categorized into inorganic and organic systems, profoundly impacts its biological behavior and therapeutic outcome [135]. Inorganic nanocarriers, such as gold nanoparticles (AuNPs) and mesoporous silica nanoparticles (MSNs), are prized for their precisely tunable size and shape, unique optical/electronic properties, and high stability [136]. For instance, AuNPs are excellent for photothermal therapy and bio-imaging, while MSNs offer immense surface area and pore volume for high drug loading [137]. However, concerns regarding their long-term biodegradation, potential for elemental toxicity, and relatively complex surface modifications for biocompatibility remain challenges [138]. In contrast, organic nanocarriers, primarily represented by liposomes and polymeric nanoparticles, are often favored for their superior biocompatibility and biodegradability. Liposomes, with their phospholipid bilayers mimicking cell membranes, provide high encapsulation efficiency for both hydrophilic and hydrophobic drugs and have pioneered clinical translation [139]. Their main limitations have been stability in circulation and premature drug leakage. Newer generations of lipid nanoparticles, as used in mRNA vaccines, have largely overcome these issues, showcasing excellent delivery efficiency and a well-established safety profile [140]. This dichotomy underscores that there is no universally superior nanocarrier. The selection is application-dependent: inorganic nanoparticles often excel in diagnostic and stimulus-responsive therapeutic roles, whereas organic carriers are typically the go-to choice for efficient and safe drug delivery, especially for nucleic acids and conventional therapeutics [141]. The evolution of nanomedicine is increasingly characterized by hybrid designs that merge the strengths of both material classes to overcome their individual limitations. Nanoparticles Nanoparticles, including liposomes and exosomes, have demonstrated superior capabilities in augmenting the solubility of pharmaceutical agents, thereby enhancing their bioavailability and extending their circulating half-life within the organism [78, 142]. These nanoparticles owe their advantageous properties to their tunable physical and chemical characteristics, which facilitate surface modification and targeted drug delivery [143, 144]. The ensuing discourse will encapsulate a comprehensive review of the current global research advancements concerning nanoparticles, with a particular emphasis on liposomes and exosomes, highlighting their therapeutic potential and the mechanisms of action in liver disease treatment [145, 146]. Liposomes In recent years, liposome-derived nanoparticles have captivated the interest of researchers and have been developed as effective delivery platforms for various drugs and mRNA to address pressing clinical needs [147]. Unlike traditional liposomes, these nanoparticles not only harness the advantages of liposomes but also exhibit a more intricate structure along with enhanced physical and chemical properties [148]. Various lipid-based liver-targeting technologies have been explored, and the exosmosis of LNPs into targeted hepatic stellate cells and hepatocytes has been illustrated through a diagram (Fig. 6A) [149]. Additionally, it has been demonstrated that both the macro- and microenvironments of liver fibrosis and HCC in vivo impede effective drug delivery (Fig. 6B). Pattipeiluhu and colleagues have introduced a novel mRNA delivery system based on liposome nanoparticles, demonstrating its capability to selectively target the hepatic reticuloendothelial system through in vivo biological distribution and clearance mechanisms by modulating the surface charge from neutral to anionic [150]. This positions it as a promising carrier system for the treatment of liver diseases. Liver-targeting lipid nanoparticle technology. (A) LNPs target liver target cells. (B) Liver fibrosis and HCC hinder drug delivery compared to normal liver. Copyright©2024, ELSEVIER Smith research has established that intravenous administration of these LNPs exhibits liver tropism, with safety and efficacy in delivery confirmed [151]. An NSG-PiZ mouse model was developed, and hepatocyte proliferation was assessed via immunofluorescence staining for hepatocyte growth factor in liver sections post-mRNA-LNP infusion (Fig. 7A). The findings indicated that treatment with HGF + EGF mRNA-LNPs enhanced the hepatic function in p21-overexpressing NSR-PIZ (p21/NSR-PIZ) mice (Fig. 7B-D). Furthermore, the study revealed that in an acute p21 overexpression model, HGF + EGF mRNA-LNP therapy elevated the survival rate of primary cells, thereby ameliorating liver pathology. Rizvi et al. similarly encapsulated nucleoside-modified mRNA in LNPs for delivery in mice, achieving immediate in vivo expression of hepatocyte growth factor [152]. The findings demonstrated that LNPs could mitigate chronic liver damage induced by NAFLD in mice, reversing steatosis and hastening hepatic function recovery (Fig. 7E-F). Collectively, mRNA-LNPs, as a delivery vehicle, are efficient, safe, and liver-specific, facilitating rapid and robust protein expression in the liver [153]. This approach has the potential to surmount significant barriers to the clinical translation of liver disease therapies [154]. Specific validation of mRNA-LNP as delivery vector promotes hepatocyte cell therapy. (A) Immunofluorescence representation of HGF + EGF mRNA-LNP after injection. Scale bar, 200 μm. (B) Quantitative map of 2C1 polymer and serum hZ-AAT levels measured by ELISA. (C) ELISA measures human serum albumin levels. (D) Serum ALT and AST levels. (E) HE staining bright field diagram analysis. Scale bar, 200 μm. (F) TUNEL representative image. Scale bar, 200 μm. Copyright©2024, nature communications Exosomes Exosomes are cell-derived nanoparticles that play a pivotal role in intercellular communication and physiological processes [155]. In contrast to liposomes, exosomes are formed from cellular membranes, rendering them more biologically active and immunogenic [156]. Their unique properties enable selective binding to the cells of their origin, enhancing their targeting capabilities [157]. Despite extensive research illustrating their potential as drug delivery systems, clinical translation continues to pose challenges due to low extraction purity and potential safety concerns [158]. Consequently, it is essential to investigate the mechanisms underlying immune escape, extraction, and targeted delivery [159]. Exosomes, serving as intercellular communication conduits, possess innate properties for drug delivery [160]. However, the conveyance of exogenous cellular material to hepatocytes by macrophages, notably Kupffer cells, presents a formidable technical hurdle [161]. Consequently, there is a pressing requirement to engineer liver-targeted exosomes for the generation of immunosurveillance [162]. Liu and colleagues developed a reprogrammed exosome loading system designed to circumvent immune surveillance mechanisms (Fig. 8A-B) [163]. Specifically, LO2 hepatocytes were engineered to overexpress CD47-HuR (designated as LO2CD47 − HuR), and exosomes were harvested via centrifugation from these cells (termed ExosCD47−HuR) using the functionalized fusion protein. It was observed that ExosCD47−HuR were efficiently internalized by LO2 cells (Fig. 8C). Furthermore, ExosCD47−HuR mitigated liver ischemia-reperfusion injury (IRI) by ameliorating mitochondrial dysfunction, achieved through the targeted delivery of CsA and miR inhibitors via electroporation (denoted as CsA/miRi@ExosCD47−HuR) (Fig. 8D). This research heralds promising clinical applications for exosome-based nanomaterials in targeting mitochondrial dysfunction for the treatment of liver IRI [164]. Reprogramming exosomes to protect mitochondria in liver IRI. (A) Schematic illustration of CsA/miRi@ExosCD47−HuR preparation. (B) CsA/miRi@ExosCD47−HuR Mechanisms that mitigate liver IRI by alleviating mitochondrial dysfunction. (C) Diagram of ExosCD47−HuR being internalized. Copyright©2024, Theranostics. (D) Schematic illustration of ExosCD47−HuR escaping phagocytosis from THP-1-M cells. Copyright©2021, J Nanobiotechnology However, this CD47-HuR reprogramming exosome can achieve the long-term integration and stable expression of therapeutic genes. However, its long-term biological safety and potential off-target genetic toxicity are the core concerns for the clinical translation of this technology [165]. The primary risk of this technique stems from the irreversibility of genomic integration. The integration event itself may disrupt the functions of key genes in the host cell. If the insertion site is near an oncogene or tumor suppressor gene, there is a potential risk of long-term driving tumor development. This delayed effect poses a severe challenge for safety assessment [166]. Additionally, the more complex issue is the off-target genetic toxicity problem. The guide RNA of the CRISPR system may mismatch with similar sequences in the genome, leading to off-target integration [167]. This unexpected double-strand break not only may randomly damage functional genes, trigger cell apoptosis or functional disorders, but also may cause large-scale chromosomal translocations or rearrangements through incorrect DNA repair mechanisms, significantly increasing genomic instability. Moreover, whether the exosomes continuously secreted by the engineered cells, as a delivery vector themselves, will transfer the genetic modification effects laterally to distant tissue cells and thereby cause toxicity, is also an urgent issue that needs to be deeply clarified as a safety concern [168]. Microneedle technologies Microneedles are an innovative physical permeability technology consisting of a series of tiny needle tips arranged in an array, with lengths that can be customized to meet individual patient needs [169]. Compared to traditional injection methods, microneedle technology enables drug delivery across biological barriers without damaging tissue or nerves [170]. Moreover, it can be developed into larger micron-sized delivery systems that disrupt the stratum corneum, facilitating the passage of larger molecules and enhancing permeability [171]. Consequently, microneedle technology offers a precise means of drug delivery, effectively overcoming conventional biological barriers to target specific tissues [172]. Currently, this technology has been extensively researched for the delivery of vaccines and therapeutics and has been applied in the treatment of various diseases [173]. Despite its numerous advantages, limitations remain, including the potential for skin irritation in individuals with sensitive skin [174]. Therefore, clinical research is essential to fully optimize microneedle technology [175]. Microneedle technology represents a pivotal advancement in the therapeutic arena for liver diseases [176]. When the microneedle patch loaded with nano-drugs is applied to the skin, it first breaks through the stratum corneum barrier through physical puncture, rapidly dissolves and releases the encapsulated nanoparticles in the dermis [177]. These nanoparticles then penetrate into the capillary and lymphatic network of the dermis and enter the systemic circulation. Subsequently, the nanoparticles achieve liver-specific enrichment through their ingenious design. This process mainly relies on the active targeting mechanism: by modifying specific ligands on the surface of the nanoparticles, they can be recognized and internalized by target cells when flowing through the liver [178]. Xu et al. have pioneered an innovative in situ implantation technique utilizing microneedle arrays, adept at delivering a consortium of therapeutic agents, including stem cells, to fibrotic liver tissues with precision, thereby offering a targeted approach to liver fibrosis, a prevalent chronic liver condition (Fig. 9A) [179]. This photothermal effect causes the local temperature at the implantation site to rise, thereby activating the proteases. The activated neutral proteases effectively catalyze the hydrolysis of soybean isolated protein, further inducing the responsive degradation of MNs and the controlled release of PtNZ and SecNPs. By establishing a mouse model of liver fibrosis and implementing in situ MN patch implantation followed by near-infrared irradiation (Fig. 9B). This method seamlessly amalgamates cell-free therapy with platinum-based nanocatalytic therapy. Through the employment of microneedle technology, hepatic stellate cells within the liver are effectively inactivated, and the excessive degradation of the ECM is significantly facilitated (Fig. 9C-D). Given that the primary mechanism underlying liver fibrosis is linked to the activation of stellate cells, this microneedle technology stands out for its ability to safeguard liver cells and potently curb the initiation and advancement of fibrosis [180]. This in situ implantation technique with microneedle arrays has demonstrated the efficacy of burgeoning microneedle technology in combating liver fibrosis, instilling optimism for its prospective clinical deployment [181]. Furthermore, the formation of liver microvascular networks is paramount to liver and tissue functionality. Li and his team have proposed a methodology for constructing liver sinusoids (Fig. 9E) [182]. They employed a 3D-printed microneedle array as a template to self-assemble a diminutive secondary liver sinusoid. This microneedle technology has effectively addressed the challenges in designing a triple-vessel liver chip with a dual-blood donor structure, providing a blueprint for the future construction of more sophisticated liver models [183]. Schematic diagram of in situ implantation of intelligent microneedle array for the treatment of liver fibrosis. (A) Schematic illustration of manufacturing and implanting an intelligent microneedle array. Copyright©2023, Advanced Science. (B) The specific method by which microneedle technology achieves liver delivery through skin application. (C) Characterization of nanoparticles fluorescence image and its quantification. (D) Fluorescence images and quantitative 3D images. Scale bar, 250 μm. (E) A simulated human hepatic acinus with a three-vessel system and its design diagram. Copyright©2023, Microsystems & Nanoengineering Microneedle-mediated drug delivery systems can effectively mitigate the needle phobia and pain associated with conventional injections, particularly for patients with chronic liver diseases who require long-term or lifelong medication regimens. This approach can significantly enhance patient adherence to treatment [184]. The sustained-release drug delivery facilitated by microneedle systems can streamline drug administration, achieve therapeutic concentrations within a specified time frame, and minimize potential systemic toxicity [185]. It substantially reduces the need for professional medical intervention, enabling patients to safely and independently administer medication in any environment, which is particularly valuable for those in regions with limited medical resources. Although microneedle technology offers superior patient compliance compared to traditional drug delivery systems, it still faces certain limitations [186]. Firstly, while microneedle technology is more advanced in skin and ocular drug delivery, its application in liver disease treatment requires further research, which undoubtedly increases the complexity of clinical translation for liver diseases. Secondly, unlike traditional subcutaneous injection needles, microneedle technology is a micrometer-sized device with a limited drug delivery capacity. Thirdly, to enhance delivery efficiency to the liver, a double-layer microneedle array system should be considered, with therapeutic drugs loaded in the microneedle layer. In conclusion, although microneedle technology shows promise in improving patient compliance for treating liver diseases, it still faces challenges in clinical translation. There remains considerable scope for the development and exploration of microneedle technology in the field of liver diseases. Biomimetic microfibers Biomimetic microfibers are synthetic materials designed to replicate the natural biological structures of organisms, such as spider silk and silkworm silk. They possess exceptional mechanical properties and biocompatibility [187]. This material has garnered significant attention owing to its lightweight nature, high tensile strength, breathability, and effective moisture absorption, enabling its application in the medical and biomanufacturing sectors [188]. Research indicates that cell-embedded microfibers can alter the structure and function of linear tissues, including cardiac and skeletal muscle [189]. Lu and his team have devised a rapid method for producing hydrogel microfibers, facilitating the creation of core-sheath ultrafine fibers and hollow ultrafine fibers infused with cells [190]. This “bottom-up” modular tissue engineering technology is increasingly demonstrating promising applications in liver treatment [191]. To rectify the imbalance between collagen deposition and degradation resulting from persistent hepatic stellate cell activation, Liang and his team devised a biomimetic nano-regulator, P-ZIF8@cirDNAzyme [192]. This nano-regulator, comprised of a platelet membrane, zeolitic imidazolate framework-8 (ZIF-8), and circular DNAzymes (cirDNAzymes), synergistically reshapes the collagen microenvironment to balance collagen metabolism in the liver. In a carbon tetrachloride-induced male liver fibrosis mouse model, P-ZIF8-cirDNAzyme demonstrated potent anti-fibrotic effects and reducing the inflammatory response (Fig. 10A-B). Du and his team developed a drug-loaded biomimetic nano delivery, CNV-C, for liver fibrosis treatment [193]. The overexpression of CCR2 on CNV-C reduces the production of liver-infiltrating macrophages and transforming growth factor β (TGF-β) (Fig. 10C-D). Collectively, this bionic microfiber engineering technology offers groundbreaking proof-of-concept for the treatment of liver diseases [194]. Liver stellate cell targeting biomimetic nano-modulator reversed liver fibrosis. (A) Schematic diagram of the preparation scheme of P-ZIF-8-cirDNAzyme. (B) P-ZIF-8-cirDNAzyme reverses the mechanism of liver fibrosis by remodeling the collagen microenvironment. (C) Adsorption experiment and transwell migration diagram of CNV-C. (D) CNV-C was characterized by CLSM image of HEK293T cells. Copyright©2023, Advanced Science In summary, biomimetic microfibers represent a novel class of biomaterials with superior biocompatibility and biomimetic capabilities, garnering increasing attention in the realm of liver regenerative medicine [195, 196]. Unlike traditional scaffolds with their rudimentary structures, nanofiber scaffolds can effectively replicate the fibrous architecture of the ECM and possess a higher specific surface area. The diameter and pore structure of nanofiber scaffolds can be readily tailored across a broad range [197]. Importantly, while traditional scaffolds primarily function as physical supports with limited versatility, and conventional treatments largely depend on such scaffolds, biomimetic microfiber scaffolds can load drugs, growth factors, or stem cells to achieve multifunctional regulation, such as antibacterial activity and angiogenesis promotion [198]. Moreover, with advanced manufacturing techniques like 3D printing, these scaffolds can be customized to match the specific lesion sites of individual patients, overcoming the size and shape limitations of traditional scaffolds. In the cutting-edge fields of liver regeneration, repair, and liver organ construction, biomimetic microfiber scaffolds hold great potential for addressing clinical challenges such as donor shortage and immune rejection [199]. They are gradually emerging as a key driving force in the development of tissue regeneration therapy, highlighting comprehensive advantages that traditional methods cannot match [200]. Additional emerging nanocarriers Beyond the aforementioned nanocarriers, innovative nanocarriers such as dendrimers and polymeric nanoparticles are anticipated to garner clinical utility in the treatment of hepatic diseases [201]. Polymeric nanoparticles are distinguished by their hydrophobic cores and ample aqueous compartments, which engender their exceptional stability and retention of physicochemical attributes, consequently extending their systemic circulation half-life [202, 203]. These conduits for drug delivery are characterized by hydrophobic shells and substantial aqueous reservoirs that facilitate the targeted conveyance of pharmaceuticals, nucleic acids, and proteins [204]. The unparalleled stability and superior biocompatibility of polymeric nanoparticles render them as highly promising vectors for delivery systems [205]. Dendritic polymers manifest unique branched architectures with escalating surface functional groups, molecular weight, and numerosity across successive generations [206, 207]. Furthermore, polymers are recognized as ideal candidates for diagnostic and therapeutic applications, attributable to the uniformity of dendrimers and the profusion of surface moieties available for conjugation with therapeutic agents, targeting ligands, or imaging reagents [208]. Alazne et al. engineered a dendritic polymer to mitigate liver inflammation and foster hepatic regeneration [209]. The dendrimer-graphite nanoparticles (DGNPs) were oxidized to generate GNPs with carboxylated surfaces, to which PAMAM 5th generation tree polymers were chemically conjugated. These polymers are known to bind nucleic acids via electrostatic interactions. The study demonstrated that DGNP-coupled plasmids induced RNF41 expression in CD11b macrophages, modulating macrophage homeostasis post-liver injury [210]. Targeting macrophage RNF41 may thus present a therapeutic strategy for nanomaterial applications in liver disease. Zhou and his team developed a system of dendrimers that emulate liver tissues, possessing multiple biological advantages and belonging to the family of hyperbranched 3D nanomolecules [211]. Specifically, norbornene-modified dendritic polymers were grafted onto PEG, enhancing biocompatibility and providing numerous cross-linking points on surface functional groups, laying groundwork for the fabrication of in vitro biological models [212]. Furthermore, polymeric nanoparticles have been instrumental in liver disease treatment. Zhao and his team constructed a polyguanide nanoinhibitors (PGNI) repository for treating NAFLD in mice [213]. The covalent polymer guanidine chain effectively ameliorated lipid accumulation by screening various ratios of nano-inhibitors. PGNI, as a targeted inhibitor, was shown to inhibit fatty acid synthesis by activating the AMPK pathway, thereby improving NAFLD, significantly advancing nanomaterial research for fatty liver disease treatment. Yee et al. developed a Methoxypoly(ethylene glycol)-poly(lactide) (mPEG-PLA) formulation coupled with resveratrol for the treatment of cancer in a murine model, enhancing resveratrol’s plasma stability and reducing its metabolic rate [214]. The co-delivery of mPEG-PLA and resveratrol exhibited stable plasma stability, decreased liver metabolic rate, and effectively inhibited tumor growth. The development of this polymer nanoparticle and drug co-delivery system offers a promising clinical strategy for HCC treatment [215]. However, the polyethylene glycol (PEG)-conjugated nanoparticles themselves may unexpectedly trigger the immune system’s alarm. When the body, especially after repeated administration, recognizes the originally inert PEG chains as foreign substances, specific anti-PEG antibodies will be produced [216]. This is the core issue of PEGylation causing immunogenicity. Once these antibodies exist, they will quickly bind to the subsequent PEG-conjugated nanoparticles. This changes the in vivo distribution of the nanoparticle carriers, induces inflammatory responses, disrupts the stability of the formulation, and even triggers hypersensitivity reactions [217]. Therefore, to avoid PEG posing a serious threat to the safety and efficacy of nanoparticle drugs, in drug development, it is necessary to carefully assess the immunogenicity risk and actively seek safer alternative strategies. Chen et al. conducted a systematic review of the immunogenicity issue of PEG and proposed multiple solutions to address this challenge [218]. These include optimizing the administration scheme of nanoparticle drugs (such as adjusting the dose, route, and time); using high-molecular-weight PEG for competitive inhibition and designing complement inhibitors to block the related immune modulation effects [219]. Liver tropism remains the benchmark for clinically validated nucleic-acid delivery: the first FDA-approved siRNA agent, Onpattro, corroborates liposomes as the most mature platform for hepatocyte targeting [220]. These vesicles transfect liver, spleen and lung with high efficiency, whereas polymeric vectors preferentially home to lung and spleen, displaying modest hepatic avidity [221]. Liposomes exhibit narrow dispersity and superior batch-to-batch uniformity, yet their encapsulation capacity is still unquantified; polymers offer analogous homogeneity, but precise control over polydispersity and segmental orientation remains elusive. Both systems accommodate disparate cargoes, although comparative loading metrics are absent. Cationic polymers, however, afford intrinsic architectural tunability—molecular-weight modulation, copolymer composition and stereoregularity—that enables bespoke vectors for extra-hepatic gene transfer, a flexibility inaccessible to lipid bilayers. Moreover, polymer nanoparticles are amenable to top-down nanofabrication (lithography, 3D nanoprinting), foretelling scalable clinical manufacture. Their chemical design space is correspondingly expansive, yet industrial translation demands resolution of polydispersity at scale, predictable biodegradation and balanced transfection potency [222]. Addressing these bottlenecks will extend polymer platforms from hepatic to systemic pathologies. Dendritic macromolecers achieve potent oncological efficacy as nanotherapeutic chemo- or gene-delivery vehicles, yet metastatic progression frequently abrogates cure. Exploiting their full nanomedicinal potential therefore necessitates orthogonal strategies to surmount drug resistance and suppress metastatic cascades [223]. Finally, the exquisite structural precision of dendrimers is offset by prohibitive synthetic cost; future efforts must streamline complexity and economize regulatory analytics to ensure clinical viability. In summary, this nano-delivery strategy exhibits superior biocompatibility and holds significant promise for clinical translation, surpassing traditional drug approaches in efficacy and safety (Fig. 11). The advantages and disadvantages of nano-delivery strategies Challenges and perspectives In recent years, liver diseases have emerged as one of the most significant health challenges facing humanity [224]. Traditional drug development has often fallen short in effectively curing liver-related conditions, and these treatments frequently result in severe adverse reactions [225]. Consequently, a range of innovative nanomaterial-based drugs has been developed, distinct from conventional medications [226]. These materials can effectively deliver small molecules, enabling their application in the clinical treatment of liver diseases, demonstrating promising therapeutic outcomes while mitigating systemic drug toxicity [227]. However, the clinical application of these emerging nanomaterials still faces numerous limitations. Therefore, we outline the challenges they encounter in the treatment of liver diseases and propose potential solutions [228]. Biocompatibility and toxicity concerns Unlike traditional drugs, emerging nanomaterials can exhibit unpredictable reactions within the human body, posing challenges related to biocompatibility and toxicity [229, 230]. These issues are significant obstacles to the clinical application of nanomedicine. Therefore, a systematic biosafety evaluation strategy should be established to assess the immunogenicity, safety, and effects of nanomaterials on liver cell function, ensuring their safety and efficacy [231]. When selecting and designing nanomaterials, priority should be given to materials with good biocompatibility, and toxicity should be minimized through surface modification [232]. Additionally, it is crucial to investigate the behavior of nanomaterials in the liver, including their metabolism, excretion pathways, and long-term effects, to gain a comprehensive understanding of their biocompatibility and toxicity [233]. To provide a more rigorous evaluation of nanomaterial biocompatibility, quantitative toxicity thresholds must be established across different platforms. For instance, silver nanoparticles (AgNPs, ~ 15 nm) exhibit significant cytotoxicity, with EC₅₀ values as low as 2.5 µg/mL for membrane integrity and 8.75 µg/mL for mitochondrial function in mammalian germline stem cells [234]. In contrast, zinc oxide nanoparticles (ZnO NPs) show an LD₅₀ of 17.5 µM in chick embryo chorioallantoic membrane assays, while metallic zinc nanoparticles are more toxic (LD₅₀ = 4.6 µM), highlighting the influence of chemical composition on toxicity. Graphene oxide (GO) nanosheets, when downsized to < 100 nm, exhibit significantly reduced cytotoxicity and improved cellular uptake, with cell viability remaining >85% at concentrations up to 50 µg/mL in LO2 hepatocytes [235]. Similarly, dual-modified nanocomplexes show IC₅₀ values of 5.54 µg/mL in LO2 cells and 3.95 µg/mL in HepG2 cells, demonstrating both cell-type specificity and relatively low toxicity [236].These comparative data underscore the necessity of size, surface charge, and chemical composition optimization in nanomaterial design. In addition to selecting the appropriate nanomaterials, the formation of the nanocarrier protein corona also affects its immunogenicity and targeting properties [237]. For instance, after adsorbing specific proteins such as immunoglobulins, complement proteins, or fibrinogen, the nanocarriers may be more easily recognized and phagocytosed by immune cells such as the abundant Kupffer cells in the liver. For example, Chen et al. in this study designed a novel protein corona targeting strategy for the formation of a nanomedicine [238]. By pre-adsorbing IgG on the surface of liposome nanomedicines, a special protein corona was formed. This structure can actively accumulate complement C3 and its cleavage product iC3b in serum. Activated neutrophils can efficiently recognize and uptake these nanomedicines that have been complement-processed, thereby targeting them to the liver inflammation sites. However, it may seriously interfere with the preset targeting function. Carefully designed targeting ligands may be deeply embedded in the protein corona and cannot be recognized by the target receptors, resulting in a decrease in targeting efficiency [239]. Therefore, a deep understanding and precise regulation of the protein corona is one of the core challenges in balancing the targeting efficiency of liver-targeting nanocarriers and their immunocompatibility, ultimately achieving their successful clinical translation. Moreover, the importance of cell-type-specific toxicity profiling, particularly for liver-targeted nanotherapies need highlight, where hepatocytes, Kupffer cells, and stellate cells may respond differentially to the same nanocarrier. Hepatic nanoparticle deposition triggers a principal clearance circuit executed by Kupffer cells, the most abundant macrophage population in vivo. Their removal arsenal encompasses phagocytosis, macropinocytosis, and receptor-mediated endocytosis via clathrin or caveolin pathways. It is worth noting that in the normal liver microenvironment, Kupffer cells possess excellent clearance capabilities. Due to their charged surfaces, positively charged nanoparticles are easily recognized and captured by negatively charged Kupffer cells for clearance. Yet this very apparatus can be subverted: lipid vectors adsorb apolipoprotein E, masquerade as endogenous lipoproteins, and are redirected to hepatocytic uptake through low-density lipoprotein receptors. Furthermore, negatively charged nanoparticles smaller than 200 nanometers can penetrate the porous liver sinusoidal endothelial cells and enter the Disse space, thereby having the opportunity to come into contact with liver cells and achieve goals such as drug delivery. However, after modification, the ability of these nanoparticles to evade Kupffer cells significantly reduces their overall transport and uptake efficiency in the liver (Fig. 12A-B) [240]. This demonstrates that Kupffer cells are the key link in mediating the liver uptake and clearance of nanoparticles. Elucidating and therapeutically tuning Kupffer-cell clearance is therefore imperative for refined liver-targeted nanotherapy. The fate of nanoparticles in the liver. (A) The pathways of nanoparticles in the liver containing Kupffer cells. (B) The reduced transport of nanoparticles in the liver without Kupffer cells. SS: sinusoidal space; LSECs: liver sinusoidal endothelial cells; DS: Disse space or perisinusoidal space. Copyright©2023, Journal of Drug Delivery Science and Technology Finally, we need to conduct a risk assessment of nanomaterials. ICH Q13 and ISO/TR 10993-22 provide a framework-based guidance from different perspectives but complementing each other [241]. In terms of control strategies, ICH Q13 requires the establishment of an overall control strategy, which clearly includes the control of input materials. The guideline emphasizes that “the impact of input material attributes and their variability on continuous processing and product quality should be assessed and proposed material attribute acceptable ranges should be justified.” This means that for nanomaterials, relying solely on traditional chemical purity standards is far from sufficient. Regulatory submissions must include a validated control strategy for their nanomaterial characteristics, such as setting strict and reasonable acceptable standards for particle size distribution, and proving that these standards are sufficient to ensure the quality of the final nanomedicine. Essentially, this involves managing and reducing the inherent higher quality risks of nanomaterials through strict control strategies compared to ordinary chemical active pharmaceutical ingredients. The ISO/TR 10993-22 document clearly states: “The manufacturing and use of nanomaterials are due to their specific properties, which may be related to the reduction in size accompanied by surface roughness.” Therefore, the evaluation of nanomaterials cannot rely solely on traditional material testing methods; special attention must be paid to factors such as “size, shape, surface properties, and/or source” of the materials. Furthermore, the document emphasizes that “merely the chemical composition is not sufficient to prove their equivalence”; it must be supported by adequate theoretical characterization and biological evaluation for their safety. Especially in the “medical device life cycle, nano-objects with a length range of 1 nm to 100 nm may be produced”. Therefore, the potential risks of the nano-objects released during “preparation, use, wear or degradation” processes to the human body must be evaluated. In conclusion, the safety evaluation of nanomaterials must be based on systematic characterization, scientific sample preparation, comprehensive toxicological studies, and dynamic risk assessment. Regulation of liver oxidative stress and ROS During the pathological process of liver diseases, oxidative stress is regarded as a core driving factor. The specific pathogenesis begins with the imbalance between the generation and clearance of ROS within cells. Liver as a metabolic factory, continuously generates ROS through physiological processes such as the mitochondrial electron transport chain and the cytochrome P450 system, including superoxide anion, hydrogen peroxide, and hydroxyl radicals [242]. Under healthy conditions, these ROS are effectively cleared by the endogenous antioxidant system, maintaining a relatively low physiological level for cell signal transduction. However, when the liver is subjected to various pathological stimuli, this balance is completely disrupted. Mitochondrial dysfunction leads to an increase in electron leakage and the production of superoxide anions; enzymes such as CYP2E1, when metabolizing exogenous toxins, also produce reactive intermediates, further promoting ROS generation [243]. At the same time, damaged liver cells and infiltrating immune cells activate multiple enzyme systems including NADPH oxidase and cause explosive growth of ROS. Persistent oxidative damage also leads to DNA mutations, which, together with liver cell apoptosis and necrosis, ultimately drive the disease from simple hepatic steatosis to liver fibrosis, cirrhosis, and even HCC. Given the central role of oxidative stress in liver diseases, regulating the balance of ROS has become a crucial therapeutic strategy. On one hand, it can directly inhibit the enzyme systems that produce ROS [244]. For example, using specific inhibitors of NADPH oxidase can reduce ROS produced after inflammatory cell infiltration; drugs that regulate mitochondrial function can improve the efficiency of the electron transport chain. On the other hand, enhancing the clearance of ROS is a more direct and widely studied strategy. Supplementing exogenous antioxidants can directly neutralize various ROS and interrupt the chain reaction of lipid peroxidation [245]. However, small molecule antioxidants often have poor stability, rapid metabolism, and weak targeting, which limits their efficacy. Additionally, regulating other pathways related to oxidative stress, such as the SIRT1/PGC-1α mitochondrial biosynthesis pathway and the AMPK energy sensing pathway, can also indirectly improve the oxidative-reductive state of cells [246]. The ideal regulatory strategy is not simply to eliminate all ROS, but to precisely intervene and restore the pathological oxidative stress level to the physiological range, thereby reconstructing the oxidative-reductive homeostasis of cells and creating favorable conditions for tissue repair. The emergence of nano-drugs provides a revolutionary tool to address the challenges faced by traditional antioxidant therapies (such as poor targeting, low stability, and insufficient bioavailability) [247]. Firstly, nano-drugs utilize their inherent size effect and functionalizable surface to achieve liver targeting. After intravenous injection, particles ranging from tens to hundreds of nanometers are easily captured by the abundant Kupffer cells and hepatic sinusoidal endothelial cells in the liver. Xiao et al. designed an amphiphilic peptide-modified gold nanoparticle cluster aggregate entity for the enrichment of liver tumors and long-term stress in the endoplasmic reticulum [248]. Mechanistically, these modified nanoparticles promote autophagy and apoptosis of liver tumor cells. Secondly, by modifying the surface of nano-particles with liver cell-specific ligands or lipid analogues to target hepatic stellate cells, the enrichment of the drug in specific target cells can be significantly enhanced, reducing off-target effects on normal tissues. Pusta et al. modified the surface of magnetic nanoparticles with aptamer molecules that specifically recognize the human HCC cell line HepG2 to ensure specificity for tumor tissues [249]. The nano-particles were further loaded with sorafenib to achieve specific activation and precise treatment at the lesion site. In conclusion, targeting liver oxidative stress is a highly promising strategy for treating a variety of liver diseases. Nanotechnology, with its excellent targeting, protective, and controlled release capabilities, has significantly enhanced the efficacy and accuracy of traditional antioxidant therapies. Nanodrugs not only overcome the pharmacokinetic deficiencies of small molecule drugs but also open up new pathways for activating endogenous defense and providing continuous antioxidant protection by delivering gene drugs and using themselves as nanoenzymes. In preclinical models, they have demonstrated significant effects in reversing hepatic steatosis, inhibiting inflammation, and delaying fibrosis. In the future, it may be necessary to develop cascade response systems that can respond to multiple microenvironmental signals (such as pH, ROS, and specific enzymes) to achieve more precise control of drug release. Scalability and cost-effectiveness of nanomedicine production Nanomaterials are costly to prepare, and their synthesis and assembly processes are often complex and time-consuming, resulting in high preparation costs. Additionally, common nanomaterials are prone to agglomeration and oxidation due to their high surface area and high energy state, leading to poor stability. Therefore, there is an urgent need to develop new nanomaterial assembly technologies to improve performance and scalability [250]. Nanocellulose is a promising nano-polymer in biomedicine, but traditional extraction methods are complex, costly, and not sustainable [251]. Kargupta et al. proposed a method using moderate refining and foam flotation to produce nanocellulose [252]. This method reduces extraction costs and labor while being highly scalable and cost-effective. This approach is a worthwhile investment in nanomaterial production technology [253]. Abbas et al. and their team modulated the self-assembly of core-shell nanocapsules using microfluidic techniques to improve drug delivery efficiency and targeting [254]. Core-shell nanocapsules are excellent for controlling drug release, improving cellular uptake, and reducing side effects due to their unique hierarchical structure [255]. This microfluidic technology greatly enhances production scalability and cost efficiency, making it a reliable strategy for nanotechnology production [256]. The synthesis of nanoparticles is a key research direction in the field of pharmaceuticals, and is widely applied in drug and gene delivery, as well as vaccine development [257]. In recent years, various types of nanomedicine carriers, such as exosomes, liposomes, and polymer nanoparticles, have received extensive attention. With the increasing demand for treatment, the development of large-scale production processes has become increasingly important. Currently, some lipid nanoparticles have successfully been transformed from laboratory to industrial production. Precision NanoSystems Inc. and Microfluidics Inc. have respectively launched the NanoAssemblr® GMP system (along with its commercial formulation system) and the M700 Microfluidizer® processor [258]. This system aims to expand the production of nanoparticles with uniform particle size and narrow particle size distribution. These industrial cases demonstrate that through technological innovation and a strict quality management system, nanomedicines can fully achieve commercial production and ultimately provide patients with breakthrough treatment options. Personalized medicine and patient-specific nanotherapies Personalized medicine is an emerging medical paradigm that tailor treatments to the specific conditions of individual patients, including their genetic profiles, environmental exposures, and lifestyle factors [259]. Given the diverse etiologies of liver diseases such as hepatitis, liver fibrosis, personalized medicine enables clinicians to identify the precise causes and pathological types through genomic analysis and advanced imaging techniques, thereby developing more targeted therapeutic strategies [260]. Additionally, the integration of physical technologies to create intuitive, accurate, and personalized anatomical models further enhances the precision of medical interventions. Patient-specific nanotherapy refers to the use of nanocarriers for precise drug delivery in treating liver diseases, thereby reducing nonspecific accumulation and minimizing adverse effects in normal cells [261]. Dul and colleagues have demonstrated the potential of peptide autoantigens combined with nanotherapy for intradermal drug administration, targeting antigen-specific immunity based on individual immune tolerance [262]. Their findings indicate that peptides conjugated with immunomodulatory elements can enhance local inflammatory responses. Moreover, the study employs gold nanoparticles to deliver drugs to specific sites, aiming to minimize immune stimulation and promote regulatory responses. Thus, patient-specific nanotherapy represents a therapeutic platform with significant clinical potential. Genomics and transcriptomics jointly provide the “biological blueprint” for the precise design of nanomedicines. Genomics reveals the inherent genetic code of patients, enabling the identification of key variations related to disease development, drug metabolism, and the biological distribution of nanoparticles. For instance, Alexa et al. identified specific overexpressed receptors (such as EGFR or HER2) within cancer cells by analyzing the tumor genome of patients [263]. This information can guide the corresponding ligand modification on the surface of nanoparticles, achieving active targeting of antigens and ensuring that the drugs can accurately target diseased cells. Transcriptomics, on the other hand, offers a more dynamic and real-time perspective, revealing which genes are actively transcribed and expressed at specific time points and in specific tissue environments. This enables the design of nanomedicines to keep pace with the progression of the disease. For example, using single-cell RNA sequencing technology, a precise cell map of TME of patients can be drawn, revealing the interacting cell subpopulations and their specific surface markers in the tumor [264]. Based on this, we can dynamically adjust the targeting strategy of nanoparticles to ensure that they can effectively respond to the heterogeneity and evolution of tumors. Furthermore, proteomics has revealed the dynamic changes in the expression levels, post-translational modifications (such as phosphorylation), and interactions of thousands of proteins in the liver after nanomedicine intervention. This directly reflects the physiological state of the cells, the activation/inhibition of signaling pathways, and potential molecular mechanisms [265]. Metabolomics provides a global picture of intracellular and small molecule metabolites. Metabolites are the ultimate executors and precise regulators of biological functions, and their changes directly reflect the real-time physiological and pathological status and energy metabolism of the cells [266]. A study based on LC-MS/MS metabolomics analysis investigated the metabolic dysfunction induced by silica nanoparticles in liver cells. It indicated that abnormal protein synthesis, protein misfolding, oxidative stress and metabolic dysfunction might lead to the hepatotoxicity induced by silica nanoparticles. It also demonstrated that metabolomics analysis can be an effective method for evaluating nanoparticle toxicity and risk assessment [267]. Therefore, the results showed that iron oxide nanoparticles could increase blood glucose concentration, and significant changes occurred in liver metabolites in the control group and the nanoparticle treatment group. Various different metabolites were discovered, and the expression of key enzymes in the changed metabolic pathways was further verified by transcriptomics. This multi-omics integration framework is driving liver nanomedicine towards more precise and rational design. By establishing the correlation between the physical and chemical properties of nanomaterials and their associated omics response characteristics, it provides molecular-level theoretical guidance for designing safer and more efficient nanocarriers. It is worth noting that artificial intelligence (AI) plays a crucial role in personalized medicine, converting complex omics data into practical and highly optimized nanoparticle design schemes. This AI-driven approach significantly accelerates the development of nanoparticles by streamlining the design of nanocarriers, optimizing drug loading and release kinetics, enhancing biocompatibility, and predicting interactions with biological barriers [268]. The advent of databases such as NanoMine and AI4Nano has facilitated the seamless integration of AI-assisted optimization and personalized nanotherapies [269]. These databases meticulously compile, organize, and standardize data on nanocarriers from extensive literature and experimental sources, encompassing their core components like polymer types and molecular weights, physicochemical properties like particle size, Zeta potential, and morphology, preparation processes, in vitro and in vivo performance such as drug loading, release curves, cell uptake, and in vivo distribution, and ultimately their therapeutic efficacy. For instance, Ma et al. illustrated how machine learning, leveraging the NanoMine database, can elucidate the relationship between the components and performance of polymer nanocomposites [270]. In summary, AI-driven approaches, supported by comprehensive databases like NanoMine and AI4Nano, are revolutionizing personalized nanotherapies by optimizing nanoparticle design and enhancing therapeutic outcomes. Clinical translation Before being put into clinical application, nano drugs and nano medical products must go through a strict regulatory approval process. This process covers systematic preclinical research and clinical trials, aiming to verify their safety, efficacy, and quality controllability. Agencies such as FDA、EMA and the NMPA are responsible for supervising this process, requiring applicants to complete comprehensive tests and scientific evaluations to meet various legal standards. When assessing the progress of clinical research for nano drugs, data from international clinical trial registration platforms like ClinicalTrials.gov can be used for analysis [271]. One of the key challenges in bringing nano drugs to mainstream treatment methods is meeting increasingly strict regulatory requirements. These requirements are the core prerequisites for ensuring product safety, effectiveness, and stable quality. Regulatory approval typically includes comprehensive preclinical and clinical evaluations, where toxicity testing and safety assessment are indispensable steps. Additionally, safety assessment also requires a series of studies to deeply understand the biocompatibility of nano drugs and their absorption, distribution, metabolism, and excretion characteristics in the body. These studies must strictly follow good laboratory practices and good manufacturing practices to ensure the reliability of experimental data and consistency between product batches. Only by fully meeting these complex regulatory requirements can nano drugs be successfully approved for market launch, providing new and safe treatment options for liver diseases and other patients [272]. Conclusion Nanomedicine holds transformative potential for clinical practice, especially in advancing the treatment of liver diseases. However, during clinical translation, the structural complexity of the human liver, the heterogeneity of disease microenvironments, and interspecies differences often lead to suboptimal performance of nanodrugs in human trials despite promising results in preclinical animal studies. Furthermore, regulatory requirements present distinct challenges. Regulatory authorities such as the FDA and NMPA mandate stringent batch-to-batch consistency in composition, physicochemical properties, and biological activity for nanodrugs. These requirements contribute to increased development costs and prolonged timelines, posing substantial barriers to industrialization. In the future, advancements are expected to address key issues related to nanomaterial-based diagnostic and therapeutic technologies, while regulatory frameworks and standards specific to nanomedicine will become increasingly standardized. Through continued progress in nanomedicine, significant breakthroughs in the management of liver diseases and broader medical applications are anticipated. Acknowledgements No. Author contributions Yawen Zhu: Investigation, Writing – original draft, Revision. Dongxue Ge: Supervision. Jinglin Wang: Project administration, Supervision. Hao Sun: Investigation, Revision. Wei Li: Conceptualization, Revision. Haozhen Ren: Conceptualization, Project administration, Supervision, Funding acquisition. Funding This work was supported by the National Natural Science Foundation of China (82270646), the Jiangsu Province Concept Verification Center-Nanjing Drum Tower Hospital Special Fund Project (2024-GNYZ-ZD-03), the Clinical Trials from Nanjing Drum Tower Hospital (2022-LCYJ-PY-35), Project of Chinese Hospital Reform and Development Institute, Nanjing University, and Aid project of Nanjing Drum Tower Hospital Health, Education & Research Foundation (NDYG2022057). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication All authors gave their consent for publication. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Hao Sun, Email: haosun_826@nju.edu.cn. Wei Li, Email: wei.li@nju.edu.cn. Haozhen Ren, Email: renhaozhen1984@163.com. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.